LAUSR

BACKGROUND S100B and Neuron-specific enolase (NSE) have been widely studied in diverse neurocritical pathologies, being recognized as the most promising biomarkers for brain injury assessment. However, their role in Intracerebral hemorrhage (ICH) has hardly been analyzed. METHODS Observational prospective cohort study of ICH patients admitted to Neurocritical Care Unit. Blood samples were collected on admission, 24, 48 and 72h. Patient's outcome was assessed at 6 months of the event . RESULTS Thirty-six ICH patients were included in the study. Mortality rate was 36%. Non-survivors had higher S100B values than survivors at admission, 24h and 48h (p<0.05). Likewise, S100B levels were higher in poor outcome patients (modified Rankin Scale [mRS]>4) than in good outcome (mRS≤3) in 24-h, 48-h and 72-h samples. ROC analysis showed that S100B on admission, 24h and 48h could discriminate between patients who survive and who die as a consequence of the ICH. The 48-h sample (AUC 0.817; p=0.003) reached the best values for sensitivity (75%) and specificity (80%), cut-off 0.250 μg/L. For 6-month functional outcome, S100B protein could differentiate between groups at 24, 48 and 72 hours. The S100B 24-h sample reached the best values for sensitivity (82.6%) and specificity (72.7%), with a cut-off of 0.202 μg/L. We found no clear relationship between NSE values and clinical characteristics. CONCLUSIONS S100B protein acts as early predictor of mortality and functional outcome in ICH patients. This biomarker measurement could provide additional information to clinical and radiological findings that could guide physicians in the management and decision-making of ICH patients.